In the first half of the 2025/26 financial year, Ypsomed completed its transformation. Following the sale of the Diabetes Care business, we are now concentrating on our core competency: innovative self-injection systems. We offer pharmaceutical and biotech companies worldwide tailor-made solutions for self-treatment – solutions based on the most comprehensive and innovative platform portfolio in our industry.

Sales and EBIT at Group level

Sales and EBIT at group level - Ypsomed

Investor Fact Sheet half-year 2025/26

Ypsomed key finacial highlights for the first half-year 2025/26.

Download the fact sheet

Semiannual Report 2025/26

Download the Semiannual Report 2025/26

Download the report

Presentation of the half-year results 2025/26

"Transforming selfcare, transforming Ypsomed"

Download the presentation

Video statement

Presentation of the half-year results 2025/26

Watch the video

Past events

12
01

44th Annual J.P. Morgan Healthcare Conference

We are pleased to announce that we will be participating in and presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, USA, on Thursday, 15 January 2026.

12
11

Media and Analyst Conference for the 2025/26 half-year results

We are pleased to announce that Ypsomed will present its 2025/26 half-year results on Wednesday, 12 November 2025, 10:00 – 11:00 a.m. CET.

Financial publications
Financial publications
Find all financial publications of Ypsomed Holding AG covering the last ten years of business activity.
Financial publications

Financial presentations
Financial Presentations
Browse Ypsomed's full archive of financial presentations held at media and investor conferences.
Financial presentations

Video statements
CEO statements
Watch all video statements held in occasion of half-year and full-year results.
Video statements

Investors' contact

Sam Ghezelbash
Head of Investor Relations and M&A
Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf
Switzerland
sam.ghezelbash@ypsomed.com
+41 76 228 51 45